Skip to content

Bone augmentation with autologous adipose tissue-derived mesenchymal stem cells and calcium phosphate carriers in the human maxillary sinus floor elevation model

Bone augmentation with autologous adipose tissue-derived mesenchymal stem cells and calcium phosphate carriers in the human maxillary sinus floor elevation model - Adipose stem cells in the sinus floor elevation model (STEM CELL LIFT)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35169
Enrollment
20
Registered
2010-05-31
Start date
2010-01-01
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

jaw bone athrophy jaw bone loss

Interventions

There will be three surgical interventions: 1. Sinus floor elevation procedure: This intervention will consist of two arms: In the first arm, the acquisition of abdominal adipose tissue, its automate

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - minimal bone height of 4 mm at planned implant site(s) - no local need for horizontal bone augmentation - healthy appearance sinus maxillaris - smoking below 10 sigarettes a day - Age 18 years or older

Exclusion criteria

Exclusion criteria: - History of malignancy or chronic infectious disease (i.e. HIV, Hepatitis) - irradiation history in jaw area - destructive sinus surgery indicated during anamnesis - endocarditis or heart valve abnormalities, or heart valve prostheses - abnormalities in the immune system, or use of immune suppressants - severe bone metabolic disorders (e.g. severe osteoporosis treated with bisphosphonates) - Chronic use (>7 consecutive days) of anticoagulants (such as aspirin) or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) within 15 days prior to lipoaspriation - Signs or symptoms of infection at the time of the surgical procedure - pregnant or nursing, or intention to become pregnant

Design outcomes

Primary

MeasureTime frame
Occurrence of any AE or SAE related to the product and/or procedure (in order to determine the follow-up regime for dose-response studies)

Secondary

MeasureTime frame
1) Radiological/clinical assessment of bone formation 2) Histological/histomorphometrical evaluation of biopsies taken 6 months after sinus floor elevation

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)